What is 18F-MFBG studying for neuroendocrine tumors?

This research is evaluating 18F-MFBG PET imaging to better detect and assess tumor burden in neuroendocrine tumors like pheochromocytoma, paraganglioma, and neuroblastoma. It aims to improve diagnosis by providing clearer images and faster procedures. The study is led by Peking Union Medical College Hospital.

Who may be eligible for this neuroendocrine tumor clinical trial?

Eligible participants are between 1 and 80 years old with a confirmed or suspected neural crest tumor such as pheochromocytoma, paraganglioma, or neuroblastoma. Both males and nonpregnant females who can follow study procedures may join. Neuroblastoma patients should have recent or planned 123I-MIBG imaging. Please review eligibility criteria for more details.

Is there any cost to participate in this neuroendocrine tumor clinical trial?

Study-related care, including the study drug or procedure and all trial visits, is provided at no cost. However, personal travel expenses may vary and are not guaranteed to be covered. Participants should plan accordingly for any travel-related costs.

Actively Recruiting

Early Phase 1

Age: 1Year - 80Years

All Genders

ID05069220

Study of 18F-MFBG PETCT Imaging to Diagnose and Measure Tumor Burden in Pheochromocytoma, Paraganglioma, and Neuroblastoma

Led by Peking Union Medical College Hospital · Updated on 2024-03-01

150

Participants Needed

Research Sites

65 weeks

Total Duration

AI-Summary

What this Trial Is About

Researchers are studying the use of 18F-metafluorobenzylguanidine 18F-MFBG positron emission tomography PET to evaluate neuroendocrine tumors, mainly pheochromocytoma, paraganglioma PPGL, and neuroblastoma NB. These tumors express norepinephrine transporter NET, which is targeted by imaging substances like 123I131I-MIBG. However, current imaging methods have limitations such as low resolution and long waiting times, which affect diagnosis. This study aims to assess the safety, image quality, diagnostic accuracy, and tumor burden detection of 18F-MFBG PET in these neural crest tumors.

CONDITIONS

Brief Title

18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor

Who Can Participate

Age: 1Year - 80Years

All Genders

Eligibility Criteria

You may qualify if you...

The participant has read, signed, and dated an informed consent form before any study procedures.
Patients have histologically confirmed or clinically suspected neural crest tumor.
Neuroblastoma patients should have routine 123I-MIBG scintigraphy (planar + SPECT/CT) within 6 months before or scheduled within 3 months after the inclusion visit.
Participants can be male or nonpregnant, nonlactating females who are surgically sterile or post-menopausal.
Participants must be able and willing to comply with all study procedures as described in the protocol.

You will not qualify if you...

Patients who are potentially pregnant or breastfeeding.
Patients who undergo surgery between selection and inclusion visits.
Patients who are pregnant, may become pregnant, or wish to become pregnant during the study period.
Patients not suitable for trial participation according to researchers.

Research Team

Peipei Wang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Study of 18F-MFBG PETCT Imaging to Diagnose and Measure Tumor Burden in Pheochromocytoma, Paraganglioma, and Neuroblastoma

On this page

AI-Summary

What this Trial Is About

Brief Title

Who Can Participate

Eligibility Criteria

Research Team

Not the Right Trial for You?

On this page

Who Can Participate

Eligibility Criteria